首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1475219

全球甲状腺疾病治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Thyroid Gland Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

在2024年至2032年的研究期间，全球甲状腺疾病治疗市场的需求预计将达到4.29%的复合年增长率。

甲状腺疾病治疗是指旨在治疗各种甲状腺疾病的医疗干预和治疗，例如甲状腺功能减退症、甲状腺功能亢进症、甲状腺结节、甲状腺肿、甲状腺癌和自体免疫甲状腺疾病（例如桥本甲状腺炎、格雷夫兹病）。治疗选择可能包括药物（例如甲状腺激素替代疗法、抗甲状腺药物）、放射性碘疗法、甲状腺切除术（手术切除甲状腺）、射频消融、乙醇消融和甲状腺癌标靶治疗。治疗选择取决于甲状腺疾病的类型和严重程度以及患者个别因素，例如年龄、整体健康状况和偏好。

市场动态

甲状腺疾病（包括甲状腺功能减退症、甲状腺功能亢进症和甲状腺结节）的发生率不断上升，推动了对有效治疗方案的需求，以控制症状、使甲状腺激素水平正常化并改善患者的生活品质。人口老化、缺碘、自体免疫疾病、环境污染物等因素导致甲状腺疾病负担日益加重。此外，医疗技术和诊断工具的进步使得准确的诊断和针对个别患者需求的个人化治疗方法成为可能，推动甲状腺疾病治疗方式的创新。此外，医疗保健领域越来越重视以患者为中心的护理、共同决策和整体管理方法，鼓励采用多学科治疗策略，将药物、生活方式改变、饮食干预和补充疗法结合起来，以获得最佳结果。

此外，病患教育措施、宣导工作和公共卫生运动提高了人们对甲状腺疾病、症状、危险因子和治疗选择的认识，使患者能够及时寻求医疗照护并遵守规定的治疗方案。随着人们越来越认识到甲状腺疾病是一个重要的公共卫生问题，以及对全面综合医疗保健服务的需求不断增长，随着医疗保健提供者和製药公司不断创新以满足患者和患者不断变化的需求，甲状腺疾病治疗市场预计将继续成长。然而，围绕新治疗方式和药物配方的监管障碍和安全担忧可能会挑战未来几年甲状腺疾病治疗市场的成长。此外，来自非专利替代品的竞争加剧和定价压力可能会阻碍市场扩张。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球甲状腺疾病治疗市场的各个细分市场进行了包容性评估。甲状腺疾病治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

甲状腺疾病治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按指示

甲状腺功能低下症
甲状腺功能亢进症

依给药途径

口服
静脉
其他的

按配销通路

批发商/分销商
零售连锁店
网上发行
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲甲状腺疾病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。甲状腺疾病治疗市场的主要参与者包括雅培、辉瑞、Lannett Company, Inc.、葛兰素史克、默克、Mylan NV、艾伯维公司、安进。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：甲状腺疾病治疗公司的竞争格局

甲状腺疾病治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Abbott

公司简介
公司收入
产品
最近的发展

Pfizer

公司简介
公司收入
产品
最近的发展

Lannett Company Inc.

公司简介
公司收入
产品
最近的发展

GlaxoSmithKline

公司简介
公司收入
产品
最近的发展

Merck KGaA

公司简介
公司收入
产品
最近的发展

Mylan NV

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Amgen.

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114332

The global demand for Thyroid Gland Disorder Treatment Market is presumed to reach with a CAGR of 4.29% under the study period 2024 - 2032.

Thyroid gland disorder treatment refers to medical interventions and therapies aimed at managing various thyroid conditions such as hypothyroidism, hyperthyroidism, thyroid nodules, goiter, thyroid cancer, and autoimmune thyroid disorders (e.g., Hashimoto's thyroiditis, Graves' disease). Treatment options may include medication (e.g., thyroid hormone replacement therapy, antithyroid medications), radioactive iodine therapy, thyroidectomy (surgical removal of the thyroid gland), radiofrequency ablation, ethanol ablation, and targeted therapies for thyroid cancer. Treatment selection depends on the type & severity of the thyroid disorder and individual patient factors such as age, overall health, and preferences.

MARKET DYNAMICS

The rising incidence of thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, drives the demand for effective treatment options to manage symptoms, normalize thyroid hormone levels, and improve patients' quality of life. Factors such as the aging population, iodine deficiency, autoimmune diseases, and environmental pollutants contribute to the increasing burden of thyroid diseases. Additionally, advancements in medical technology and diagnostic tools enable accurate diagnosis and personalized treatment approaches tailored to individual patient needs, driving innovation in thyroid gland disorder treatment modalities. Moreover, the growing emphasis on patient-centric care, shared decision-making, and holistic management approaches in healthcare encourages the adoption of multidisciplinary treatment strategies that combine medication, lifestyle modifications, dietary interventions, and complementary therapies for optimal outcomes.

Furthermore, patient education initiatives, advocacy efforts, and public health campaigns raise awareness about thyroid disorders, symptoms, risk factors, and treatment options, enabling patients to seek timely medical attention and adhere to prescribed treatment regimens. With the increasing recognition of thyroid disorders as a significant public health concern and the growing demand for comprehensive and integrated healthcare services, the thyroid gland disorder treatment market is predicted to continue growing as healthcare providers and pharmaceutical companies innovate to address the evolving needs of patients and improve clinical outcomes. However, regulatory hurdles and safety concerns surrounding new treatment modalities and drug formulations may challenge the growth of the thyroid gland disorder treatment market in the coming years. Additionally, increasing competition from generic alternatives and pricing pressures could impede market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thyroid gland disorder treatment. The growth and trends of thyroid gland disorder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thyroid gland disorder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

Hypothyroidism
Hyperthyroidism

By Route Of Administration

Oral
Intravenous
Others

By Distribution Channel

Wholesalers/Distributors
Retail Chain
Online Distribution
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thyroid Gland Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thyroid Gland Disorder Treatment market include Abbott, Pfizer, Lannett Company, Inc., GlaxoSmithKline, Merck KGaA, Mylan N.V., AbbVie Inc., Amgen. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. THYROID GLAND DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Indication
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

5.1. Overview By Indication
5.2. Historical and Forecast Data
5.3. Analysis By Indication
5.4. Hypothyroidism Historic and Forecast Sales By Regions
5.5. Hyperthyroidism Historic and Forecast Sales By Regions

6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data
6.3. Analysis By Route of Administration
6.4. Oral Historic and Forecast Sales By Regions
6.5. Intravenous Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Wholesalers/Distributors Historic and Forecast Sales By Regions
7.5. Retail Chain Historic and Forecast Sales By Regions
7.6. Online Distribution Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE THYROID GLAND DISORDER TREATMENT COMPANIES

9.1. Thyroid Gland Disorder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF THYROID GLAND DISORDER TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Pfizer
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Lannett Company Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GlaxoSmithKline
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Merck KGaA
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Mylan N.V.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. AbbVie Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Amgen.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments